FDA approves J & J ’s Tremfya self-injection pen for psoriasis
FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis. The self-injection approval may help Tremfya compete with AbbVie’s (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients. Get the full story on our sister site, Drug Delivery Business. The post FDA approves J&J’s Tremfya self-injection pen for psoriasis appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 30, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Drug-Device Combinations Food & Drug Administration (FDA) News Well AbbVie Janssen Pharmaceuticals johnsonandjohnson Source Type: news

Drug Companies Greet 2019 With U.S. Price Hikes Drug Companies Greet 2019 With U.S. Price Hikes
Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world ' s top-selling medicine, Humira, although the pace of price hikes was slower than last year.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 17, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Drug companies greet 2019 with U.S. price hikes
Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year. (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Lilly drug shown to be more effective than Humira in late-stage study
Eli Lilly Co. released results from a study this week showing that its drug, Taltz, was better at treating psoriatic arthritis than Humira. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 17, 2018 Category: Pharmaceuticals Source Type: news

Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
INDIANAPOLIS, Dec. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the ef... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis, SPIRIT-H2H trial (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 17, 2018 Category: Pharmaceuticals Source Type: news

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - December 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

The Little-Known Way Pharma Companies Hook People On Their Costly Drugs
Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. The 36-year-old psychologist had run into an increasingly common problem: The copay coupon sent by Amgen couldn’t cover the drug’s more than $4,000 monthly price. “Nothing in the world gives me more anxiety than just getting my medication,” Burgess said. “There’s nothing you can do but beg.” Panicked, Burgess had called Amgen and pleaded for help. The drugmaker sent him the check after he provided a credit card statement and an explanat...
Source: TIME: Health - December 12, 2018 Category: Consumer Health News Authors: Sarah Jane Tribble / Kaiser Health News Tags: Uncategorized Drugs Source Type: news

Pfizer reaches a global agreement with AbbVie
Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer's proposed adalimumab biosimilar for many countries around the world. (Source: World Pharma News)
Source: World Pharma News - December 4, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Adalimumab biosimilar will save drug costs for NHS England
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news

AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
NORTH CHICAGO, Ill., Nov. 30, 2018 -- (Healthcare Sales & Marketing Network) -- AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant... Biopharmaceuticals, Generics, Licensing AbbVie, Pfizer, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 30, 2018 Category: Pharmaceuticals Source Type: news

NHS ditches its most expensive drug used by 46,000 arthritis sufferers
Health  bosses have signed a deal to save £300million a year by using cheaper versions of a costly arthritis drug. More than 46,000 English patients take adalimumab, which had been £400million a year. (Source: the Mail online | Health)
Source: the Mail online | Health - November 26, 2018 Category: Consumer Health News Source Type: news

NHS ditches its most expensive drug used by 46,000 arthritis sufferers in bid to save £300million
Health  bosses have signed a deal to save £300million a year by using cheaper versions of a costly arthritis drug. More than 46,000 English patients take adalimumab, which had been £400million a year. (Source: the Mail online | Health)
Source: the Mail online | Health - November 26, 2018 Category: Consumer Health News Source Type: news

NHS set to save £300 million on NHS’s highest drug spend
Biosimilar versions of adalimumab to be introduced Related items fromOnMedica Cancer Drugs Fund ‘wasteful and harmful’ The medicine price debate Drug prices may rise for NHS after Brexit NHS saves £324m by switching to cheaper medicines (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 26, 2018 Category: UK Health Source Type: news

Paradoxical Development of Panuveitis and Granulomatous Interstitial Lung Disease Associated with Adalimumab Therapy for Psoriasis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news